Delvin Surgicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -27.31%
(FY 2023)
- Profit 44.98%
(FY 2023)
- Ebitda -1994.76%
(FY 2023)
- Net Worth -1.29%
(FY 2023)
- Total Assets 4.38%
(FY 2023)
About Delvin Surgicals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Jaganathan Jayaseelan and Ayyavu Rajavel serve as directors at the Company.
- CIN/LLPIN
U33110TN2015PTC101631
- Company No.
101631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Delvin Surgicals Private Limited offer?
Delvin Surgicals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Pain Killers.
Who are the key members and board of directors at Delvin Surgicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jaganathan Jayaseelan  | Director | 31-Jul-2015 | Current |
| Ayyavu Rajavel | Director | 31-Jul-2015 | Current |
Financial Performance of Delvin Surgicals.
Delvin Surgicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.31% decrease. The company also saw a substantial improvement in profitability, with a 44.98% increase in profit. The company's net worth dipped by a decrease of 1.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delvin Surgicals?
In 2023, Delvin Surgicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saimirra Innopharm Private LimitedActive 24 years 10 monthsJaganathan Jayaseelan and Ayyavu Rajavel are mutual person
Inventz Life Sciences Private LimitedActive 7 years 9 monthsJaganathan Jayaseelan is a mutual person
Nuray Chemicals Private LimitedActive 12 years 7 monthsJaganathan Jayaseelan and Ayyavu Rajavel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Delvin Surgicals?
Unlock and access historical data on people associated with Delvin Surgicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delvin Surgicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delvin Surgicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
